Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-02-02 18:00 |
Biophytis sera présent à plusieurs événements sectoriels au cours du 1er semest…
|
French | 617.8 KB | ||
| 2018-02-02 18:00 |
Biophytis to participate in upcoming sectorial events over the first half of 20…
|
English | 708.2 KB | ||
| 2017-12-08 07:30 |
Biophytis présente 4 posters sur Sarconeos à la 10ème conférence internationale…
|
French | 755.1 KB | ||
| 2017-12-08 07:30 |
Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on C…
|
English | 743.9 KB | ||
| 2017-12-04 07:45 |
Biophytis obtient l’autorisation de l’AFMPS pour conduire l’étude de phase 2b S…
|
French | 823.5 KB | ||
| 2017-12-04 07:45 |
Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study …
|
English | 784.6 KB | ||
| 2017-11-01 07:30 |
Biophytis réalise avec succès une augmentation de capital de 7,5 M€ pour accélé…
|
French | 762.2 KB | ||
| 2017-11-01 07:30 |
Biophytis completes a € 7,5 M capital increase to help accelerate pipeline prog…
|
English | 820.3 KB | ||
| 2017-10-30 07:45 |
Biophytis a l’approbation de la FDA pour lancer l’étude interventionnelle de ph…
|
French | 826.3 KB | ||
| 2017-10-30 07:45 |
Biophytis has FDA Approval to initiate SARA-INT phase 2b Interventional Study o…
|
English | 533.3 KB | ||
| 2017-10-27 07:45 |
Biophytis nomme le professeur Thomas Voit à son comité scientifique pour l’aide…
|
French | 821.0 KB | ||
| 2017-10-27 07:45 |
Biophytis appoints Professor Thomas Voit to Scientific Advisory Board to help a…
|
English | 530.8 KB | ||
| 2017-10-11 07:30 |
Biophytis réalise avec succès une augmentation de capital de 10,4 M€ pour finan…
|
French | 769.9 KB | ||
| 2017-10-11 07:30 |
Biophytis completes a €10.4 M capital increase to finance mid-stage clinical tr…
|
English | 831.8 KB | ||
| 2017-09-25 07:45 |
Biophytis a déposé la demande d’IND pour approbation par la FDA de l’étude de …
|
French | 763.7 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
